Vir Biotechnology Inc (VIR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Vir Biotechnology Inc stock (VIR) is currently trading at $8.99. Vir Biotechnology Inc PS ratio (Price-to-Sales) is 20.61. Analyst consensus price target for VIR is $20.78. WallStSmart rates VIR as Underperform.
- VIR PE ratio analysis and historical PE chart
- VIR PS ratio (Price-to-Sales) history and trend
- VIR intrinsic value — DCF, Graham Number, EPV models
- VIR stock price prediction 2025 2026 2027 2028 2029 2030
- VIR fair value vs current price
- VIR insider transactions and insider buying
- Is VIR undervalued or overvalued?
- Vir Biotechnology Inc financial analysis — revenue, earnings, cash flow
- VIR Piotroski F-Score and Altman Z-Score
- VIR analyst price target and Smart Rating
Vir Biotechnology Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Vir Biotechnology Inc (VIR) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, eps growth. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Vir Biotechnology Inc (VIR) Key Strengths (4)
Revenue surging 417.80% year-over-year
Earnings per share surging 58.50% year-over-year
70.16% of shares held by major funds and institutions
Trading at 1.90x book value, attractively priced
Supporting Valuation Data
Vir Biotechnology Inc (VIR) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 20.6x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Vir Biotechnology Inc (VIR) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 8 metrics analyzed, 4 register as strengths (avg 9.5/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, EPS Growth, Institutional Own.. Valuation metrics including Price/Book (1.90) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 417.80%, EPS Growth at 58.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (20.61) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -45.70%, Operating Margin at -74.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -45.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 417.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VIR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VIR's Price-to-Sales ratio of 20.61x trades at a deep discount to its historical average of 1023.3x (63th percentile). The current valuation is 100% below its historical high of 9345.44x set in Jul 2020, and 2976% above its historical low of 0.67x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~12.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Vir Biotechnology Inc (VIR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Vir Biotechnology Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 69M with 418% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 418% YoY, reaching 69M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 129% of revenue (88M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -30M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Vir Biotechnology Inc maintain 418%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.71, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Vir Biotechnology Inc.
Bottom Line
Vir Biotechnology Inc is a high-conviction growth story with revenue accelerating at 418% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Vir Biotechnology Inc(VIR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.